P
Paul O'Donnell
Researcher at Royal National Orthopaedic Hospital
Publications - 176
Citations - 9678
Paul O'Donnell is an academic researcher from Royal National Orthopaedic Hospital. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 42, co-authored 166 publications receiving 8177 citations. Previous affiliations of Paul O'Donnell include Nuffield Orthopaedic Centre & Harvard University.
Papers
More filters
Journal ArticleDOI
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
Leo Luznik,Paul O'Donnell,Paul O'Donnell,Heather J. Symons,Allen R. Chen,M. Susan Leffell,Marianna Zahurak,Ted Gooley,Ted Gooley,S Piantadosi,Michele Kaup,Richard F. Ambinder,Carol Ann Huff,William Matsui,Javier Bolaños-Meade,Ivan Borrello,Jonathan D. Powell,Elizabeth Harrington,Sandy Warnock,Mary E.D. Flowers,Mary E.D. Flowers,Robert A. Brodsky,Brenda M. Sandmaier,Brenda M. Sandmaier,Rainer Storb,Rainer Storb,Richard J. Jones,Ephraim J. Fuchs +27 more
TL;DR: Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD, and there was a trend toward a lower risk of extensive chronic GVHD (cGVHD) among recipients of 2 versus 1 dose of posttrans transplantation Cy.
Journal ArticleDOI
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M Fernanda Amary,Krisztian Bacsi,Francesca Maggiani,Stephen Damato,Dina Halai,Fitim Berisha,Robin Pollock,Paul O'Donnell,Anita Grigoriadis,Tim C. Diss,Malihe Eskandarpour,Nadege Presneau,Pancras C.W. Hogendoorn,Andrew Futreal,Roberto Tirabosco,Adrienne M. Flanagan,Adrienne M. Flanagan +16 more
TL;DR: IDH1 and IDH2 mutations represent the first common genetic abnormalities to be identified in conventional central and periosteal cartilaginous tumours and speculate that a mosaic pattern of IDH‐mutation‐bearing cells explains the reports of diverse tumours (gliomas, AML, multiple cartILaginous neoplasms, haemangiomas) occurring in the same patient.
Journal ArticleDOI
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea,Mei-Jie Zhang,Andrea Bacigalupo,Asad Bashey,Frederick R. Appelbaum,Omar S. Aljitawi,Philippe Armand,Joseph H. Antin,Junfang Chen,Steven M. Devine,Daniel H. Fowler,Leo Luznik,Ryotaro Nakamura,Paul O'Donnell,Miguel-Angel Perales,Sai Ravi Pingali,David L. Porter,Marcie L. Riches,Olle Ringdén,Vanderson Rocha,Ravi Vij,Daniel J. Weisdorf,Richard E. Champlin,Mary M. Horowitz,Ephraim J. Fuchs,Mary Eapen +25 more
TL;DR: It is suggested that survival for patients with AML after haploidentical transplantation with posttransplant cyclophosphamide is comparable with matched unrelated donor transplantation.
Journal ArticleDOI
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
Claudio G. Brunstein,Ephraim J. Fuchs,Shelly L. Carter,Chatchada Karanes,Luciano J. Costa,Juan Wu,Steven M. Devine,John R. Wingard,Omar S. Aljitawi,Corey Cutler,Madan Jagasia,Karen K. Ballen,Mary Eapen,Paul O'Donnell +13 more
TL;DR: These multicenter studies confirm the utility of dUCB and Haplo-marrow as alternative donor sources and set the stage for a multicenter randomized clinical trial to assess the relative efficacy of these 2 strategies.
Journal ArticleDOI
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide
Paul O'Donnell,L. Luznik,Richard J. Jones,Georgia B. Vogelsang,Mary S. Leffell,Michele Phelps,P. Rhubart,Kathleen Cowan,S Piantadosi,Ephraim J. Fuchs +9 more
TL;DR: It is demonstrated that partially HLA-mismatched bone marrow can engraft rapidly and stably after nonmyeloablative conditioning that includes posttransplantation Cy, even among patients who reject their donor grafts.